Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Designation crawled date : 2021 - 04 - 22 save search
Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA and Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase (OTC) Gene Therapy ProgramPhase 3 Study on Track to Initiate in Second Half 2021
Published: 2021-04-22 (Crawled : 14:00) - biospace.com/
RARE | $43.38 -1.65% -1.68% 770K
|
Health Technology
|
| O: 0.39%
H: 2.14%
C: -0.64%
fda phase 2 gene therapy therapy phase 3 gene therapies designation
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience
Published: 2021-04-22 (Crawled : 12:00) - globenewswire.com
AKTX | $1.225 9.26% 8.47% 8.8K
|
Health Technology
|
| O: 2.09%
H: 1.23%
C: -0.41%
presentation disease trial designation
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.